SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-134805
Filing Date
2024-05-09
Accepted
2024-05-09 08:10:55
Documents
15
Period of Report
2024-05-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d774503d8k.htm   iXBRL 8-K 23621
2 EX-99.1 d774503dex991.htm EX-99.1 19248
6 GRAPHIC g774503g0509050007428.jpg GRAPHIC 6894
  Complete submission text file 0001193125-24-134805.txt   184146

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA cgon-20240509.xsd EX-101.SCH 2876
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cgon-20240509_lab.xml EX-101.LAB 18736
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cgon-20240509_pre.xml EX-101.PRE 11724
18 EXTRACTED XBRL INSTANCE DOCUMENT d774503d8k_htm.xml XML 3768
Mailing Address 400 SPECTRUM CENTER DRIVE SUITE 2040 IRVINE CA 92618
Business Address 400 SPECTRUM CENTER DRIVE SUITE 2040 IRVINE CA 92618 (949) 419-6203
CG Oncology, Inc. (Filer) CIK: 0001991792 (see all company filings)

IRS No.: 371611499 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41925 | Film No.: 24928707
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)